Key Highlights
- First-of-its-kind collaboration between Bayer and Hologic aims to improve breast cancer diagnosis with a new mammography solution.
- The solution integrates Hologic’s advanced mammography technologies with Bayer’s MEDRAD® Stellant FLEX CT Injection System.
- To be showcased at the Society of Breast Imaging Symposium, April 2024 in Montreal, Canada.
Source: Business Wire
Notable Quote
- “We are thrilled to work with Hologic to increase access to this emerging breast imaging modality,” – Sven Schmidt, Head of Region Americas Radiology at Bayer
SoHC's Take
This collaboration between Bayer and Hologic signifies a substantial advancement in the field of mammography, particularly in contrast-enhanced techniques. By combining their respective technologies, the two companies are setting a new standard in the accessibility and effectiveness of breast cancer diagnostics. This initiative not only highlights the ongoing innovations in medical imaging but also emphasizes the importance of integrated solutions in improving patient outcomes in oncology care settings. With their combined expertise, Bayer and Hologic are poised to make significant contributions to women’s health globally.
